Tetrathiomolybdate
Wilson Disease
Floatz Rating
B62/100
Confidence
Indicative
Sponsor
National Center for Research Resources (NCRR)
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00004339CT.gov Study of Tetrathiomolybdate in Patients With Wilson Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Wilson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tetrathiomolybdate (this asset) | National Center for Research Resources (NCRR) | P3 | B · 62 |
| Zinc Acetate | Nobelpharma | P4 | BBB |
| Teta 4Hcl | Orphalan | P3 | BBB |
| Zinc D-Gluconate (1:2) | Jun Li | P4 | BBB |
| Trientine | Excelsior | P3 | BB |
| Penicillamine | Orphalan | P3 | BB |
| Alxn1840 | Alexion Pharmaceuticals, Inc. | P3 | BB |
| Gandouling | Jun Li | P4 | BB |
| Bis-Choline Tetrathiomolybdate | Alexion Pharmaceuticals, Inc. | P2 | B |
+11 more in the Wilson Disease cohort
Other indications for Tetrathiomolybdate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Biliary Cholangitis | — | P3 | BB · 64 |
| Hepatocellular Carcinoma | — | P2 | B · 57 |
| Colorectal Carcinoma | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Tetrathiomolybdate in Wilson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/tetrathiomolybdate-wilson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →